



COMMONWEALTH of VIRGINIA
Department of Medical Assistance Services

CYNTHIA B. JONES
DIRECTOR

November 15, 2012

SUITE 1300
600 EAST BROAD STREET
RICHMOND, VA 23219
804/786-7933
800/343-0634 (TDD)
www.dmas.virginia.gov

MEMORANDUM

TO: The Honorable Walter A. Stosch
Chairman, Senate Finance Committee

The Honorable Lacey E. Putney
Chairman, House Appropriations Committee

The Honorable Linda T. Puller
Chairman, Joint Commission on Health Care

Daniel S. Timberlake
Director, Virginia Department of Planning and Budget

FROM:

Cynthia B. Jones

A handwritten signature in black ink that reads "Cynthia Jones".

SUBJECT: Report on Specialty Drug Program

Item 307 (T) of the 2012 Appropriations Act requires the Department of Medical Assistance Services to report on savings and quality improvements for the specialty drug program to the Chairmen of the Senate Finance and House Appropriations Committees, the Joint Commission on Health Care, and the Department of Planning and Budget by November 1 of each year. I have enclosed for your review the report for 2012.

Should you have any questions or need additional information, please feel free to contact me at (804) 786-8099.

Enclosure

Cc: The Honorable William A. Hazel, Jr., M.D., Secretary of Health and Human Resources

Annual Report on the Specialty Drug Program



Virginia Department of Medical Assistance Services

November 1, 2012

Authority for Report

Item 307 (T) (1) of the 2012 Appropriations Act directs the Department of Medical Assistance Services (DMAS) to modify the delivery system of pharmaceutical products to include a specialty drug program, in consultation with physicians, pharmacists, pharmaceutical manufacturers, patient advocates, the Pharmacy Liaison Committee, and others as appropriate. A copy of the Appropriations Act language is provided in Attachment A. This report responds to the requirement in Item 307 (T) (5) that the Department annually report on the cost savings and quality improvements achieved through the program.

Overview

Specialty drugs are a category of prescription medications that have grown out of advances in drug development research, technology, and design. These drugs are used to treat specific chronic or genetic conditions. Specialty drugs include biological drugs, blood-derived products, complex molecules, and select oral and injectible medications. They typically require tailored patient education for safe and cost-effective use, patient-specific dosing, close patient monitoring, administration (via injection or orally), and refrigeration or other special handling. All these factors contribute to the high cost of specialty drugs which has a direct impact on DMAS' prescription drug expenditures. National cost trends suggest that specialty drugs and injectibles are the highest growing category of covered drugs. This trend is expected to continue as more injectible and specialty drugs receive FDA approval to address chronic diseases, such as Multiple Sclerosis, Cancer, Arthritis and others.

The DMAS Specialty Drug Program (SMAC) was implemented in July of 2008 to address issues of cost effectiveness and appropriate utilization. The drug classes priced under the DMAS SMAC program include: (1) hematopoietic agents (Anemia); (2) anti-tumor necrosis factor agents (Rheumatoid Arthritis); (3) immunomodulator agents (used to regulate or normalize the immune system); (4) agents to treat Muscular Sclerosis; (5) growth hormones; and, (6) interferon agents for hepatitis C. As of the date of this report, the SMAC reimbursement amount is determined by the SMAC rate of Wholesale Acquisition Cost (WAC) + 4.75%, the Federal Upper Payment Limit, the estimated acquisition cost of Average Wholesale Price – 13.1%, or the pharmacy's usual and customary charge, whichever is less. The class of drugs priced under the SMAC program has remained unchanged since the program's inception. Changes to the estimated acquisition cost of single source innovator drugs, however, significantly reduced the number of specialty drugs priced using the SMAC rate in fiscal year 2012.

SMAC Program Expenditures

Table 1 provides specialty drug pricing data for state fiscal years 2011 and 2012. The table identifies unique recipients, the number of claims and total reimbursement of claims for specialty drugs that fall under the specialty drug program.

Table 1

Specialty Drug Claims	FY 2011	FY 2012	% Change
Total Recipients	647	700	+8%
Total Claims	3802	3680	-3%
Total Dollar Amount	8,001,773	8,360,659	+3%
Dollar Amount per Claim	2104.62	2272.00	+8%

Table 2 is a subset of the claims identified in Table 1 that were reimbursed using the SMAC pricing logic of WAC + 4.75%.

Table 2

Specialty Drug Claims Priced at WAC + 4.75%	FY 2011	FY 2012	% Change
Total Recipients	487	63	-87%
Total Claims	2414	131	-95%
Total Dollar Amount	\$5,345,071	\$172,692	-97%

The per claim increase in costs of 8% for specialty drug claims under the SMAC program from the prior fiscal year mirrors national trends of higher acquisition costs for this category of drugs. DMAS saved approximately \$149,760 in FY 2011 with the use of the SMAC rate of 4.75%. In FY 2012, DMAS saved approximately \$4,968. This savings amount reflects the lower reimbursement rate of AWP-13.1% for single source innovator drugs, which went into effect during FY 2012.

Upcoming SMAC Program Initiatives

DMAS is currently exploring ways to modify the current specialty drug program that increases the quality of the services provided to patients, and the health outcomes of patients who receive specialty drugs both through the pharmacy benefit and the medical benefit. DMAS is looking closely at the experience of other state Medicaid programs in terms of:

- How they price specialty drugs;
- How they contract with specialty pharmacies;
- The appropriate level of clinically appropriate ancillary services required for patients who are dispensed specialty drugs; and
- Their overall approach to specialty drug benefit management.

The current SMAC reimbursement rate of WAC + 4.75% for specialty drugs priced under the SMAC is also under review by DMAS. With the permanent change of the estimated acquisition cost for single source, innovator drugs to AWP – 13.1% in July of 2011, many specialty drugs previously reimbursed under the SMAC pricing logic are being reimbursed at AWP – 13.1%, reducing its relevance. Any change in the reimbursement rate used by the SMAC program, however, will be carefully considered in light of the unique nature of specialty drugs, as well as the cost and availability of these drugs to Virginia’s specialty pharmacies.

Acknowledgements

DMAS wishes to acknowledge the contributions of its Pharmacy & Therapeutics Committee, the Drug Utilization Review Board, the Pharmacy Liaison Committee, representatives of the pharmacy community, and pharmaceutical manufacturers who are assisting the Department in developing an effective specialty drug program that is consistent with the intent of the Appropriations Act. The collaborative efforts of the provider community will be essential to the continued success of a specialty drug program.

ATTACHMENT A

Item 307 (T) of the 2012 Appropriations Act

T.1. The Department of Medical Assistance Services may amend the State Plan for Medical Assistance Services to modify the delivery system of pharmaceutical products to include a specialty drug program. In developing the modifications, the department shall consider input from physicians, pharmacists, pharmaceutical manufacturers, patient advocates, the Pharmacy Liaison Committee, and others as appropriate.

2. In developing the specialty drug program to implement appropriate care management and control drug expenditures, the department shall contract with a vendor who will develop a methodology for the reimbursement and utilization through appropriate case management of specialty drugs and distribute the list of specialty drug rates, authorized drugs and utilization guidelines to medical and pharmacy providers in a timely manner prior to the implementation of the specialty drug program and publish the same on the department's website.

3. In the event that the Department of Medical Assistance Services contracts with a vendor, the department shall establish the fee paid to any such contractor based on the reasonable cost of services provided. The department may not offer or pay directly or indirectly any material inducement, bonus, or other financial incentive to a program contractor based on the denial or administrative delay of medically appropriate prescription drug therapy, or on the decreased use of a particular drug or class of drugs, or a reduction in the proportion of beneficiaries who receive prescription drug therapy under the Medicaid program. Bonuses cannot be based on the percentage of cost savings generated under the benefit management of services.

4. The department shall: (i) review, update and publish the list of authorized specialty drugs, utilization guidelines, and rates at least quarterly; (ii) implement and maintain a procedure to revise the list or modify specialty drug program utilization guidelines and rates, consistent with changes in the marketplace; and (iii) provide an administrative appeals procedure to allow dispensing or prescribing provider to contest the listed specialty drugs and rates.

5. The department shall report on savings and quality improvements achieved through the implementation measures for the specialty drug program to the Chairmen of the House Appropriations and Senate Finance Committees, the Joint Commission on Health Care, and the Department of Planning and Budget by November 1 of each year.

6. The department shall have authority to enact emergency regulations under § 2.2-4011 of the Administrative Process Act to effect these provisions.